Sukumar Nagendran

President and Head of R&D

Sukumar Nagendran (President and Head of R&D) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Taysha Gene Therapies, Inc. (TSHA). The largest single filing was $1.7M of TSHA (370,172 sh across 2 lots, as filed), executed Nov 28 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 5 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$5.3M

shares × price, as filed

Last traded

Jul 10

Filed Jul 10

Median ADV $19.6M across their filed names

Open performance→

Volume by month

Buys $0 Sells $6.1M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 5 filings

Sector per market data · by filing · past 12 months

Most traded names

TSHA

Taysha Gene Therapies, Inc. TSHA · 0 buys · 7 sells 7 filings

Recent filings

TSHASALE Taysha Gene Therapies, Inc. View filing → $1.2M
200,000 sh × $6.24
Exec Jul 10
Filed Jul 10 · 6:54 PM ET TSHASALE Taysha Gene Therapies, Inc. View filing → $892K
200,000 sh × $4.46
Exec Apr 10
Filed Apr 13 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. View filing → $547K
116,050 sh across 2 lots
Exec Jan 23
Filed Jan 27 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. View filing → $942K
200,000 sh × $4.71
Exec Jan 12
Filed Jan 14 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. View filing → $1.7M
370,172 sh across 2 lots
Exec Nov 28 2025
Filed Dec 1 2025 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. View filing → $646K
200,000 sh × $3.23
Exec Sep 10 2025
Filed Sep 12 2025 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. View filing → $163K
57,054 sh × $2.85
Exec Aug 21 2025
Filed Aug 22 2025 · 5:30 PM ET